Literature DB >> 18475820

Effect of Copper Acyclovir Complexes on Herpes Simplex Virus Type 1 and Type 2 (HSV-1, HSV-2) Infection in Cultured Cells.

M Panteva1, T Varadinova, I Turel.   

Abstract

We have found that when copper, zinc or cobalt is bound to a suitable ligand, the appropriate complex exhibited a significant anti-HSV effect (Varadinova et al., 1993; 1996). Recently published data by Sagripanti et al. (1997) also show that the inhibition of HSV by copper was enhanced by reducing agents and that mechanism of the inactivation is similar as for copper-mediated DNA damage (Aruoma, et al. 1991; Dizdaroglu, et al., 1991; Toyokuni and Sagripanti, 1994). Therefore it was interesting to study the efect of Cu(ll) coordination compounds with acyclovir (ACV) on the replication of HSV in cultured cells. The experiments on cytotoxicity as well as on the activity of three different Cu-ACV complexes [Cu(ACV)(2)Cl(2)(H(2)O)(2)] = (A); [Cu(ACV)(2)(H(2)O)(3)](NO(3))(2).H(2)O = (B) and [Cu(ACV)(2)(H(2)O)(2)](NO(3))(2)] = (C) towards virus replication, with special attention on the growth of ACV-resistant strain R-100 were performed on MDBK cells. ACV was used as a reference compound. The following results were obtained: 1) Increased cell's viability in the presence of 20-40(g/ml ACV and decreased one in the presence of Cu-ACV complexes with relative level (A) >> (B) > (C); 2) Cu-ACV complexes are more cytotoxic than the ligand - ACV and the relative level is (C)>(B)>(A); 3) The anti-HSV effect of ACV can be modulated by copper at levels depending on the specificity of the particular virus strain: (i) for the ACV sensitive strain DA (HSV-1) - ACV ((A) > (C) > (B); (ii) for the ACV sensitive strain Bja (HSV-2) (A) > ACV > (C) > (B); (iii) for strain R-100 (ACV(R), TK(a)) - (A) > ACV > (C) > (B). This findings are consistent with previously published data and undoubtedly show that Cu-ACV complexes could be useful in the treatment of HSV infections, especially when the causative agent is a resistant to ACV mutant.

Entities:  

Year:  1998        PMID: 18475820      PMCID: PMC2365095          DOI: 10.1155/MBD.1998.19

Source DB:  PubMed          Journal:  Met Based Drugs        ISSN: 0793-0291


  3 in total

1.  Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Authors:  Ji Young Yoo; Jason Pradarelli; Amy Haseley; Jeffrey Wojton; Azeem Kaka; Anna Bratasz; Christopher A Alvarez-Breckenridge; Jun-Ge Yu; Kimerly Powell; Andrew P Mazar; Theodoros N Teknos; E Antonio Chiocca; Joseph C Glorioso; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

Review 2.  Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells.

Authors:  Dhaval S Sanchala; Lokesh K Bhatt; Kedar S Prabhavalkar
Journal:  Front Pharmacol       Date:  2017-05-16       Impact factor: 5.810

3.  ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma.

Authors:  Ji Young Yoo; Jun-Ge Yu; Azeem Kaka; Quintin Pan; Pawan Kumar; Bhavna Kumar; Jianying Zhang; Andrew Mazar; Theodoros N Teknos; Balveen Kaur; Matthew O Old
Journal:  Mol Ther Oncolytics       Date:  2015-05-20       Impact factor: 7.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.